Aster DM Healthcare has successfully completed its strategic acquisition in the renewable energy sector, purchasing a 26% stake in Oyster Green Hybrid Two Private Limited for a revised consideration of ₹5.80 crore. The healthcare major announced the completion of this acquisition on April 23, 2026, marking a significant milestone in its renewable energy initiative.

Acquisition Completion Details

The company has completed the acquisition through a two-tranche payment structure, with the final tranche completed on April 22, 2026. The investment details are outlined below:

The total consideration was revised from the originally agreed ₹7.00 crore to ₹5.80 crore pursuant to a reduction in the overall project cost. The Group, comprising Aster DM Healthcare and its material subsidiary Malabar Institute of Medical Sciences Limited (MIMS), has completed the acquisition of 26% of the equity share capital of Oyster Green Hybrid Two.

Project Specifications

The acquisition enables Aster DM Healthcare to establish an 18 MWp captive solar power plant in Kerala. Oyster Green Hybrid Two will build, develop, install, commission, operate, manage, and maintain the solar power facility. The company and its material subsidiary MIMS will purchase 100% of the net output electricity generated from this captive solar power plant.

Target Company Profile

Oyster Green Hybrid Two Private Limited was incorporated on January 22, 2024, and is engaged in building, developing, installing, commissioning, operating, and maintaining solar power plants across India. The company's financial position shows:

Strategic Impact

This acquisition represents Aster DM Healthcare's commitment to sustainable energy solutions and operational cost optimization. The 26% stake acquisition complies with statutory requirements under the Electricity Act, which mandates that captive users hold not less than 26% ownership in such projects. The captive solar power plant will provide dedicated clean energy capacity, supporting the company's environmental sustainability goals while ensuring energy security for its healthcare facilities in Kerala.

Aster DM Healthcare has received a positive outlook from HSBC, with the global brokerage firm raising its target price significantly while maintaining an optimistic stance on the healthcare provider's business prospects.

HSBC Rating and Target Price Revision

HSBC has upgraded its target price for Aster DM Healthcare to ₹755, representing a substantial increase from the previous target of ₹635. The brokerage continues to maintain its Buy rating on the stock, reflecting confidence in the company's growth trajectory and operational performance.

Q4FY26 Performance Expectations

The brokerage expects steady performance from Aster DM Healthcare in Q4FY26, supported by several positive operational factors. Key drivers for the optimistic outlook include a anticipated pickup in elective procedures, which typically contribute significantly to hospital revenues and margins.

Business Growth and Expansion Strategy

HSBC highlights the company's continued capital expenditure expansion as a positive factor in its assessment. The ongoing capex investments are expected to support long-term growth, despite creating some near-term margin pressures from new unit operations.

Key Growth Factors:

• Elective Procedures Recovery: Expected pickup in elective medical procedures
• Expansion Strategy: Continued capital expenditure for business growth
• Operational Efficiency: Sustained healthy operating trends across hospital business
• Margin Management: Manageable new unit margin drag

Hospital Business Performance Outlook

The brokerage notes sustained healthy operating trends across Aster DM Healthcare's hospital business segment. While new units may create some margin pressure initially, HSBC considers this drag to be manageable and expects the overall business to maintain its positive trajectory.

The combination of operational improvements, strategic expansion, and recovery in elective procedures positions the company favorably for continued growth in the healthcare sector.